Meanwhile, the adverse event occurrence (Grade≥3) has increased from 9.7% (nivolumab) to 18.9% (relatlimab and nivolumab) (NCT03470922).51 Another current phase 3 trial evaluating the efficacy of LAG-3 blocking antibody (MK-4280 and REGN3767) and LAG-3 bispecific (MGD013) in HER2+ gastric and gastroesophageal junction cancer patients (NCT04082364), PD-1+ colorectal cancer patients (NCT05064059) and melanoma (NCT05352672) are ongoing. Here, LAG3 is linked to melanoma.